Xtant Medical Holdings Inc Dossier - Source-backed chat

Xtant Medical Holdings Inc

XTNTNYSE

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.23

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.36Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $49.8M

Enterprise Value $51M

Shares Outstanding 141.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Xtant Medical Holdings, Inc. (XTNT) is undergoing a strategic transformation, sharpening its focus on its core, higher-margin biologics business following the divestiture of its non-core Coflex/CoFix assets and international hardware business to Companion Spine in December 2025. While the loss of non-recurring license revenues and divested assets will result in a year-over-year revenue decline in fiscal 2026, the company has significantly strengthened its balance sheet, reducing total indebtedness by $13.3 million in Q1 2026. The exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows product, along with the integration of Dilon's sales force, expands Xtant's addressable market and prompted management to raise its FY2026 revenue guidance to $101M-$105M. Trading at a low valuation multiple relative to its historical performance and peers, XTNT offers a compelling risk-reward profile as it targets self-sustainability and positive free cash flow in 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$0.60

Mean target$1.05

High · most bullish analyst$1.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The integration of Dilon's sales force faces operational friction, and the core biologics business fails to offset the loss of divested hardware and license revenues. Continued softness in the surgical procedure environment or competitive pressures in the orthobiologics space limit organic growth, causing the company to miss its revised FY2026 revenue guidance and delay its path to free cash flow positivity.

Base CaseCentral scenario

The company successfully integrates Dilon's HEMOBLAST Bellows product and sales team, driving top-line growth within the raised guidance range of $101M-$105M. Core biologics organic growth accelerates, offsetting the gross margin pressure from the loss of high-margin amniotic license revenues. The company achieves positive free cash flow and returns to positive Adjusted EBITDA in the second half of 2026.

Bull CaseUpside scenario

The bull case for Xtant Medical centers on its strategic transition into a pure-play regenerative medicine and biologics company. By divesting its non-core, lower-margin Coflex and international hardware businesses to Companion Spine for $21.4 million, Xtant has significantly strengthened its balance sheet, eliminated debt, and improved liquidity. This allows the company to focus resources on its high-margin biologics portfolio (such as the newly launched Strata synthetic bone graft) and expand its independent agent network and field sales force to drive organic growth and sustainable profitability.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Significantly strengthened balance sheet with total debt reduced by $13.3 million in Q1 2026, leaving a net cash-neutral position.
Strategic pivot to higher-margin core biologics and high-performance hemostasis markets via the exclusive Dilon HEMOBLAST Bellows agreement.
Management expects to be free cash flow positive in fiscal 2026 with no near-term need for dilutive outside capital raises.

Key Investment Risks

Near-term margin compression due to the cessation of high-margin Q-code amniotic membrane license revenues.
Execution and integration risk associated with absorbing Dilon's 20-person U.S. sales team.
Highly competitive orthobiologics and spinal implant market dominated by larger, better-capitalized players.

Thesis Invalidation Triggers

Failure to achieve positive free cash flow or positive Adjusted EBITDA by the end of fiscal 2026.
A material downward revision of the fiscal 2026 revenue guidance below the $101M midpoint.
Loss of key independent distributors or failure of new product lines like Trivium Shaped to gain market traction.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.